Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest International AIDS Vaccine Initiative Stories

2010-11-04 08:27:00

ATLANTA, Nov. 4, 2010 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project ("QTDP") program. GeoVax received the maximum level allowable under the program based on the...

2010-10-18 06:30:00

ATLANTA, Oct. 18 /PRNewswire/ -- Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN). In the article, titled "Search for Effective HIV Vaccine Intensifies: Progress to Date Result of Robust Funding and Cooperation...

2010-10-17 20:10:00

SHANGHAI, Oct. 17 /PRNewswire-Asia/ -- At the end of 2009, the vaccine industry raised so much concern worldwide that the headlines of the business media were occupied by various kinds of news about vaccine enterprises. For example, Sinovac Biotech Co., Ltd. successfully landed on the Nasdaq, then Simcere, a pharmaceutical company based in Jiangsu Province, listed on the NYSE, announced a 50.8% stake in Ealong Biotech and took control of the latter, and finally Novartis, the world-famous...

2010-10-01 06:30:00

ATLANTA, Oct. 1 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, presented the results of a study using granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant for the GeoVax DNA/MVA vaccine at the AIDS Vaccine 2010 conference held in Atlanta from September 28 to October 1. The talk, given on Thursday, September 30 in...

2010-09-30 20:12:56

As researchers and policymakers work toward an effective HIV vaccine in a constrained global economy, cost-effective prevention strategies such as Couples Voluntary Counseling and Testing (CVCT) must take a larger role in efforts to decrease the rates of HIV/AIDS in Africa, says Emory University HIV/AIDS vaccine researcher Susan Allen, MD, MPH. Allen, who has worked to combat the AIDS epidemic in Africa for more than 25 years, highlighted the value of CVCT and other cost-effective HIV...

2010-09-27 06:30:00

ATLANTA, Sept. 27 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, will present the results of a study using granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant for the GeoVax DNA/MVA vaccine at the AIDS Vaccine 2010 conference to be held in Atlanta from September 28 to October 1. The talk, to be given on Thursday,...

2010-09-07 18:03:00

NEW YORK, Sept. 7 /PRNewswire-USNewswire/ -- AVAC welcomes the new Global HIV Vaccine Enterprise Scientific Strategic Plan, released today, as a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research. The Plan comes at a crucial time in the field. In the last year, the RV144 Thai vaccine trial proved that an AIDS vaccine is possible, which along with...

2010-09-07 06:30:00

ATLANTA, Sept. 7 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announces that Chief Executive Officer Dr. Robert McNally will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference. The presentation is currently scheduled for 12:30 PM, September 14, 2010, in the Winslow Salon, 5th Floor of the New York Palace Hotel in New York City. Dr. McNally said, "The Rodman and...

2010-08-27 07:00:00

ATLANTA, Aug. 27 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced the results of its Annual Shareholders Meeting, held on August 24, 2010. During the meeting, shareholders re-elected seven nominees for directors of the company to serve until the 2011 Annual Meeting of Shareholders and until their successors are duly elected or appointed and qualified. They are:...

2010-08-17 07:00:00

ROCKVILLE, Md., Aug. 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the IMVAC Summit. The Conference will take place August 17-19, 2010 at the Royal Sonesta Hotel, Cambridge, MA. Dr. Steven Pincus will be presenting, "Influenza Virus-Like Particle Vaccine Produced in Insect Cells Elicits Hemagglutination and Neuraminidase Inhibiting Antibodies in Immunized Health Adults," on Tuesday, August...